C4 Therapeutics (CCCC) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 62.7% versus a gain of 31.1%. C4 Therapeutics is the larger company by market cap ($388.8 million vs $364.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | TTRX |
|---|---|---|
| Share price | $3.16 | $12.00 |
| Market cap | $388.76M | $364.41M |
| 1-day change | +10.88% | +5.36% |
| YTD return | +65.45% | +189.09% |
| 1-year return | +31.12% | +62.71% |
| 5-year return | -92.80% | — |
| EPS (TTM) | $-1.01 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $16.45 |
| 52-week low | $1.69 | $2.57 |
| Distance from 52-week high | -38.88% | -27.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +306.96% | +108.33% |
| Average volume | 2.38M | 110.43K |
| Shares outstanding | 123.03M | 30.37M |
| Employees | 104 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed CCCC by 31.6 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Healthcare · Biotechnology · 2 employees
CCCC vs TTRX FAQ
Which is bigger, C4 Therapeutics or Turn Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $388.76M compared with $364.41M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, CCCC or TTRX?
TTRX returned +62.71% over the past 12 months, compared with +31.12% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.